These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 13965577)

  • 1. Contribution of serum and cellular factors in host defense reactions. I. Serum factors in host resistance.
    AUSTEN KF; COHN ZA
    N Engl J Med; 1963 May; 268():994-1000 contd. PubMed ID: 13965577
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum properdin, complement and agglutinin changes in dogs with staphylococcal bacteremia.
    BALTCH AL; OSBORNE W; CANARILE L; HASSIRDJIAN A; BUNN PA
    J Immunol; 1962 Mar; 88():361-8. PubMed ID: 13864522
    [No Abstract]   [Full Text] [Related]  

  • 3. EVIDENCE FOR IMMUNOLOGICAL SPECIFICITY OF THE PROPERDIN SYSTEM; DEMONSTRATION, ISOLATION AND PROPERTIES OF A SERUM FACTOR WHICH INTERACTS WITH ZYMOSAN AND OTHER POLYSACCHARIDES AT 0 DEGREES CENTIGRADE.
    BLUM L
    J Immunol; 1964 Jan; 92():61-72. PubMed ID: 14139548
    [No Abstract]   [Full Text] [Related]  

  • 4. [NATURAL INNATE IMMUNITY FOR BRUCELLA MELITENSIS. I. RELATION WITH PROPERDIN, COMPLEMENT, BACTERICIDAL PROPERTIES OF SERUM AND THE FORMATION OF SPECIFIC ANTIBODIES].
    LEON AP; OSOLLO G; CANO C
    Rev Inst Salubr Enferm Trop; 1962 Dec; 22():145-72. PubMed ID: 14076958
    [No Abstract]   [Full Text] [Related]  

  • 5. The antibody-complement system and properdin. A review.
    MUSCHEL LH
    Vox Sang; 1961 Jul; 6():385-97. PubMed ID: 14477525
    [No Abstract]   [Full Text] [Related]  

  • 6. Contribution of serum and cellular factors in host defense reactions. I. Serumfactors in host resistanc.
    AUSTEN KF; COHN ZA
    N Engl J Med; 1963 Apr; 268():933-8 contd. PubMed ID: 13965576
    [No Abstract]   [Full Text] [Related]  

  • 7. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on serum complement and properdin levels in patients with pulmonary tuberculosis].
    OSAWA T
    Kekkaku; 1959 Oct; 34():711-9. PubMed ID: 14429184
    [No Abstract]   [Full Text] [Related]  

  • 10. Partial properdin deficiency.
    Davis CA; Forristal J
    J Lab Clin Med; 1980 Oct; 96(4):633-9. PubMed ID: 6903190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HUMORAL FACTORS IN CELLULAR RESISTANCE. II. THE ROLE OF COMPLEMENT AND PROPERDIN IN PHAGOCYTOSIS AND CYTOPEPSIS BY NORMAL AND "IMMUNE" MACROPHAGES.
    WU WG; MARCUS S
    J Immunol; 1964 Mar; 92():397-403. PubMed ID: 14128985
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement activation by tubular cells is mediated by properdin binding.
    Gaarkeuken H; Siezenga MA; Zuidwijk K; van Kooten C; Rabelink TJ; Daha MR; Berger SP
    Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1397-403. PubMed ID: 18753294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of guinea-pig serum complement for its use in properdin assay using inulin.
    MAJUMDAR AC; SEN R; MUKERJI B
    Ann Biochem Exp Med; 1962 Aug; 22():209-12. PubMed ID: 14468640
    [No Abstract]   [Full Text] [Related]  

  • 14. SOME OBSERVATIONS IN RELATION TO PROPERDIN SYSTEM. IV. RELATION OF SERUM COMPLEMENT ACTIVITY AND PROPERDIN LEVEL OF NORMAL ALBINO RATS TO STREPTOMYCIN THERAPY AND DIET.
    SEN R; MATHUR PD; MAJUMDAR AC
    Ann Biochem Exp Med; 1963 Dec; 23():577-82. PubMed ID: 14154202
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of anticomplementary substances on properdin in normal and C2-deficient sera.
    McLean RH; Townsend K; Michael AF
    Clin Exp Immunol; 1975 Mar; 19(3):435-44. PubMed ID: 1204244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
    Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
    J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway of complement: nonenzymatic, reversible transition of precursor to active properdin.
    Götze O; Medicus RG; Müller-Eberhard HJ
    J Immunol; 1977 Feb; 118(2):525-32. PubMed ID: 839069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CONTRIBUTION TO THE STUDY OF THE PHYSIOPATHOLOGY OF PREVENTIVE ANTIPERTUSSIS VACCINATION. II. EFFECTS OF ANTIPERTUSSIS VACCINATION ON NATURAL FACTORS OF IMMUNE RESISTANCE].
    DELCAMPO A; ZARDINI V
    G Mal Infett Parassit; 1965 Jun; 17():319-26. PubMed ID: 14346720
    [No Abstract]   [Full Text] [Related]  

  • 19. [Nonspecific resistance in germ-free and E. coli monocontaminated miniature piglets].
    Podoprigora GI
    Biull Eksp Biol Med; 1978 Sep; 86(9):341-4. PubMed ID: 359062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properdin: emerging roles of a pattern-recognition molecule.
    Kemper C; Atkinson JP; Hourcade DE
    Annu Rev Immunol; 2010; 28():131-55. PubMed ID: 19947883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.